Stock Forecast

  Artelo Biosciences, Inc. ( ARTL) Stock. Should you Buy or Sell?    $ 3.90

0.14 (3.47 %)



Artelo Biosciences, Inc. Analysis

Updated on 10-09-2022
Symbol ARTL
Price $3.90
Beta 1.251
Volume Avg. $343.41 thousand
Market Cap $11.07 M
52 Week Range $3.61 - $19.8


Artelo Biosciences, Inc. opened the day at $3.90 which is +'3.47 % on yesterday's close. Artelo Biosciences, Inc. has a 52 week high of $19.8 and 52 week low of $3.61, which is a difference of $16.19. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $11.07 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Artelo Biosciences, Inc. for $11.07 M, it would take 15 years to get your money back. Artelo Biosciences, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Artelo Biosciences, Inc. Stock Forecast - Is Artelo Biosciences, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -18.712
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Artelo Biosciences, Inc.


Price Book Value Ratio 6.946 Price To Book Ratio 6.946
Price To Sales Ratio 0.000 Price Earnings Ratio -18.712


How liquid is Artelo Biosciences, Inc.


Current Ratio 42.281
Quick Ratio 36.685


Debt


Debt Ratio 0.023 Debt Equity Ratio 0.024
Long Term Debt To Capitalization 0.002 Total Debt To Capitalization 0.004



Latest news about Artelo Biosciences, Inc.


Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12 - 14, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

Date : 07/09/2022

Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

Date : 17/08/2022

Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) --   Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California.

Date : 01/06/2022

Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th

SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.

Date : 16/05/2022

Artelo Biosciences to Present at MicroCap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.

Date : 13/05/2022





About Artelo Biosciences, Inc.


CEO : Mr. Gregory D. Gorgas
Sector : Healthcare
Industry : Biotechnology

Website : https://www.artelobio.com

Exchange : NASDAQ Capital Market

Description :

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.


My Newsletter

Sign Up For Updates & Newsletters